4 February 2021

MaxCyte announces £40 million subscription

MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, has raised gross proceeds of £40 million (US$55 million) through a private placement of common stock. Subscribers included new investors D1 Capital Partners, T. Rowe Price, ArrowMark Partners, Baron Capital Group and First Light Asset Management, alongside existing investors Casdin Capital and Sofinnova Partners.

Doug Doerfler, President & Chief Executive Officer of MaxCyte, expressed his delight at the new life science specialist investors. He said that the financing would strengthen the company's balance sheet as it accelerates revenue growth in 2021 and marked a further step towards the company's goal to dual-list on Nasdaq in 2021.

There has been a 464.5% increase in the company's share price over the last 12 months, indicating strong investor interest in genomics and asset allocations to life sciences. MaxCyte's Flow Electroporation® Technology enables its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy.

Working with Panmure Gordon, LGB introduced investors to MaxCyte's fundraisings in 2017 and 2019. The fundraisings, which benefitted from EIS, were conducted at 275p and 170p per share respectively. The placing just announced was conducted at 700p.


Recent Articles

28 April 2021

The start of a supercycle?

With the UK government last year announcing that green hydrogen was to be central to the country’s ‘green industrial revolution' and the EU’s hydrogen roadmap forecasting €500bn being invested in the transition to a hydrogen-based economy by 2050, Read more

News & Insights

26 April 2021

Time Finance - Latest Issue

We are pleased to announce the successful completion of a £2 million note issuance under the Time Finance plc (formerly 1pm plc) MTN programme. 

Read more


20 April 2021

Market Commentary - Q1 2021

Q1 2021 was marked in the UK, and the US which continues to set the tone for world markets, by cautious optimism that the vaccine rollout will work, and that economies will restart. Read more

News & Insights